Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Blood (2018) 132 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood-2018-120738

Published: 2018

Journal Articles

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Gary E. Raskob, PhD, Nick Van Es, MD, Peter Verhamme, MD PhD, Marc Carrier, MD, Marcello Di Nisio, MD, David A. Garcia, MD, Michael A. Grosso, MD, Ajay K. Kakkar, MBBS, Michael J. Kovacs, MD, Michele F. Mercuri, MD PhD FAHA, Guy Meyer, MD, Annelise Segers, MD, Minggao Shi, PhD, Tzu-Fei Wang, MD, Erik Yeo, MD FACP, FRCPC, George Zhang, PhD, Jeffrey I. Zwicker, MD, Jeffrey I. Weitz, MD, Harry R. Büller, MD PhD

Blood (2017) 130 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-6.LBA-6

Published: 2017

Journal Articles

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial

Annie Young, PhD, Andrea Marshall, PhD, Jennifer Thirlwall, BSc, Catherine Hill, BSc, Danielle Hale, MA, Janet Dunn, PhD, Anand Lokare, MD FRCPath, MRCP, Ajay K. Kakkar, MBBS, Mark N. Levine, MD MSC, Oliver Chapman, MBBS, FRCPath, MRCP

Blood (2017) 130 (Supplement 1): 625.

https://doi.org/10.1182/blood.V130.Suppl_1.625.625

Published: 2017

Journal Articles

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Sebastian Schellong, MD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Martin Feuring, MD, Stefan Hantel, PhD, Jörg Kreuzer, MD, Sam Schulman, MD PhD, Ajay K Kakkar, MB, BS, PhD

Blood (2015) 126 (23): 4730.

https://doi.org/10.1182/blood.V126.23.4730.4730

Published: 2015

Journal Articles

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Sam Schulman, MD, PhD, Ajay K Kakkar, MD, Sebastian M Schellong, MD, Samuel Z. Goldhaber, MD, Eriksson Henry, MD, PhD, Patrick Mismetti, MD, PhD, Anita Vedel Christiansen, MSc.Pharm., Janet Schnee, MD, Clive Kearon, MB, PhD

Blood (2011) 118 (21): 205.

https://doi.org/10.1182/blood.V118.21.205.205

Published: 2011

Journal Articles

The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery

Ajay K. Kakkar, MBBS, PhD, Giancarlo Agnelli, William D. Fisher, MD, Daniel George, Patrick Mouret, Michael R. Lassen, MD, Patrick Mismetti, Judith Murphy, Alexander G.G. Turpie

Blood (2010) 116 (21): 188.

https://doi.org/10.1182/blood.V116.21.188.188

Published: 2010

Journal Articles

Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.

Sam Schulman, Henry Eriksson, Samuel Z. Goldhaber, Ajay K Kakkar, MD, PhD, Clive Kearon, Patrick Mismetti, Sebastian M Schellong, David Baanstra, Janet Schnee

Blood (2009) 114 (22): 1.

https://doi.org/10.1182/blood.V114.22.1.1

Published: 2009

Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP

Blood (2009) 114 (22): 2099.

https://doi.org/10.1182/blood.V114.22.2099.2099

Published: 2009

Journal Articles

Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.

Ajay K Kakkar, PhD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Victor F Tapson, MD, Jean-Francois Bergmann, MD, Samuel Z. Goldhaber, MD, Frederick A Anderson, Jr., PhD

Blood (2008) 112 (11): 984.

https://doi.org/10.1182/blood.V112.11.984.984

Published: 2008

Journal Articles

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, PhD, Bengt Eriksson, MD, PhD, Frank Misselwitz, MD, Tiemo Joerg Bandel, MD, Martin Homering, Torsten Westermeier, PhD, Michael Gent, DSc

Blood (2008) 112 (11): 36.

https://doi.org/10.1182/blood.V112.11.36.36

Published: 2008

Journal Articles

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.

Bengt Eriksson, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, PhD, Frank Misselwitz, MD, Tiemo Joerg Bandel, Martin Homering, Torsten Westermeier, Michael Gent, MD

Blood (2008) 112 (11): 1986.

https://doi.org/10.1182/blood.V112.11.1986.1986

Published: 2008

Journal Articles

Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey

Ajay K Kakkar, PhD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Victor F Tapson, MD, Jean-Francois Bergmann, MD, Samuel Z. Goldhaber, MD, Frederick A Anderson, Jr., PhD

Blood (2008) 112 (11): 171.

https://doi.org/10.1182/blood.V112.11.171.171

Published: 2008

Journal Articles

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Ajay K. Kakkar, MD, PhD, Benjamin Brenner, MD, Ola E. Dahl, MD, PhD, Bengt I. Eriksson, MD, PhD, Patrick Mouret, MD, Jim Muntz, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD, Sylvia Haas, MD

Blood (2007) 110 (11): 307.

https://doi.org/10.1182/blood.V110.11.307.307

Published: 2007

Journal Articles

Venous Thromboembolic Risk and Suboptimal Prophylaxis in the US Acute Hospital Care Setting: Findings from the ENDORSE Study.

Victor F. Tapson, Alexander T. Cohen, Jean-Francois Bergmann, Samuel Goldhaber, Ajay K. Kakkar, Frederick A. Anderson

Blood (2007) 110 (11): 1858.

https://doi.org/10.1182/blood.V110.11.1858.1858

Published: 2007

Journal Articles

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Richard J. Friedman, MD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Tiemo J. Bandel, MD, Eva Muehlhofer, MD, Frank Misselwitz, MD, William Geerts, MD

Blood (2007) 110 (11): 6.

https://doi.org/10.1182/blood.V110.11.6.6

Published: 2007

Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD

Blood (2006) 108 (11): 903.

https://doi.org/10.1182/blood.V108.11.903.903

Published: 2006

Journal Articles

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Alexander G.G. Turpie, MD, Kenneth Alan Bauer, MD, Lars Borris, MD, Ola E. Dahl, MD, PhD, William D. Fisher, MD, Michael Gent, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Louis M. Kwong, MD, Martin Homering, PhD, Frank Misselwitz, MD, PhD, Bengt I. Eriksson, MD, PhD

Blood (2005) 106 (11): 277.

https://doi.org/10.1182/blood.V106.11.277.277

Published: 2005

Journal Articles

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Bengt I. Eriksson, MD, PhD, Lars Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Frank Misselwitz, MD, PhD, Eva Muehlhofer, PhD, Peter Kälebo, MD, PhD

Blood (2005) 106 (11): 280.

https://doi.org/10.1182/blood.V106.11.280.280

Published: 2005

Journal Articles

Rates of Clinically Apparent Venous Thromboembolism and Death Resulting from Pulmonary Embolism among Unselected Hospitalized Acutely Ill Medical Patients Versus Rates Predicted from Clinical Studies.

Franco Piovella, MD, Frederick A. Anderson, Jr., PhD, Hervé Decousus, MD, Gordon FitzGerald, Jean-François Bergmann, MD, Ajay K. Kakkar, MD, PhD, Alex C. Spyropoulos, MD, Rainer B. Zotz, MD, Frederick A. Spencer, MD, Alexander G.G. Turpie, MD, for the IMPROVE Investigators

Blood (2005) 106 (11): 1620.

https://doi.org/10.1182/blood.V106.11.1620.1620

Published: 2005

Journal Articles

The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients.

Victor F. Tapson, Herve Decousus, Jean-Fran[ccedi]ois Bergmann, Beng H. Chong, James B. Froehlich, Ajay K. Kakkar, Geno J. Merli, Manuel Monreal, Mashio Nakamura, Riccardo Pavanello, Mario Pini, Franco Piovella, Alex C. Spyropoulos, Alexander G.G. Turpie, Rainer B. Zotz, Gordon FitzGerald, Frederick A. Anderson, Jr, for the IMPROVE investigators

Blood (2004) 104 (11): 1762.

https://doi.org/10.1182/blood.V104.11.1762.1762

Published: 2004

NARROW

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery

Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.

Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Venous Thromboembolic Risk and Suboptimal Prophylaxis in the US Acute Hospital Care Setting: Findings from the ENDORSE Study.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Rates of Clinically Apparent Venous Thromboembolism and Death Resulting from Pulmonary Embolism among Unselected Hospitalized Acutely Ill Medical Patients Versus Rates Predicted from Clinical Studies.

The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only